Odanacatib: location and timing are everything
S Khosla - Journal of Bone and Mineral Research, 2012 - academic.oup.com
Antiresorptive drugs have become the mainstay for the prevention and treatment of
osteoporosis. Members of this class include estrogen, the selective estrogen receptor …
osteoporosis. Members of this class include estrogen, the selective estrogen receptor …
Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women
JL Pérez-Castrillón, F Pinacho, D De Luis… - Journal of …, 2010 - Wiley Online Library
Osteoclasts are specialized cells that initiate the process of bone resorption, which has two
phases, dissolution of the mineral component and degradation of the organic matrix, in …
phases, dissolution of the mineral component and degradation of the organic matrix, in …
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics–results from single oral dose studies …
SA Stoch, S Zajic, JA Stone, DL Miller… - British journal of …, 2013 - Wiley Online Library
Aims To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
odanacatib (ODN), a cathepsin K inhibitor, in humans. Methods Two double‐blind …
odanacatib (ODN), a cathepsin K inhibitor, in humans. Methods Two double‐blind …
[HTML][HTML] Therapeutic inhibition of cathepsin K—reducing bone resorption while maintaining bone formation
LT Duong - BoneKEy reports, 2012 - ncbi.nlm.nih.gov
Osteoporosis is a disease of high bone remodeling with an imbalance of bone resorption
over bone formation, resulting in decreased bone mineral density and deterioration of bone …
over bone formation, resulting in decreased bone mineral density and deterioration of bone …
Pharmacological inhibition of cathepsin K: a promising novel approach for postmenopausal osteoporosis therapy
K Mukherjee, N Chattopadhyay - Biochemical pharmacology, 2016 - Elsevier
Osteoporosis is a metabolic bone disease that is characterized by heightened state of bone
resorption accompanied by diminished bone formation, leading to a reduction of bone …
resorption accompanied by diminished bone formation, leading to a reduction of bone …
[PDF][PDF] Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling
EM Lewiecki - Drugs, 2009 - panoramaortho.com
Odanacatib (MK· 0822, MK-822) is an orally administered cathepsin K inhibitor being
developed by Merck & Co Inc, under license from Ce/era Croup, for the treatment of …
developed by Merck & Co Inc, under license from Ce/era Croup, for the treatment of …
Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits
BL Pennypacker, RM Oballa, S Levesque… - BMC musculoskeletal …, 2013 - Springer
Background Selective and reversible inhibitors of human Cathepsin K (CatK), including
odanacatib (ODN), have been developed as potential therapeutics for the treatment of …
odanacatib (ODN), have been developed as potential therapeutics for the treatment of …
Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized …
T Nakamura, M Shiraki, M Fukunaga… - Osteoporosis …, 2014 - Springer
The efficacy and safety of oral placebo or odanacatib 10, 25, or 50 mg once weekly for 52
weeks were evaluated in a double-blind, randomized, multi-center study in Japanese female …
weeks were evaluated in a double-blind, randomized, multi-center study in Japanese female …
Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence
CAF Zerbini, MR McClung - Therapeutic advances in …, 2013 - journals.sagepub.com
Human bones are in a continuous process of remodeling that ensures renovation and
maintenance of the skeletal mass. Bone remodeling has two phases that are normally …
maintenance of the skeletal mass. Bone remodeling has two phases that are normally …